Welcome to our dedicated page for Jazz Pharmaceuticals Plc SEC filings (Ticker: JAZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Jazz Pharmaceuticals plc filings document material events for an Ireland-domiciled biopharmaceutical issuer with Nasdaq-listed ordinary shares. Recent 8-K reports furnish quarterly and annual financial results, guidance, corporate presentations and product-level commentary for Xywav, Epidiolex, Modeyso and oncology launches.
The company’s filings also record clinical and regulatory disclosures for Ziihera (zanidatamab-hrii) and the HERIZON-GEA-01 program, board and committee changes, standard director compensation and indemnification arrangements, and settlement agreements involving patent and related commercial disputes. These records tie Jazz’s capital-market disclosures to its neuroscience and oncology portfolio, governance structure and material business events.
Mark D. Smith, a director of Jazz Pharmaceuticals plc (JAZZ), reported two related equity transactions. On 08/07/2025 he was recorded as acquiring 3,507 restricted stock units (RSUs) under the companys 2007 Non-Employee Directors Stock Award Plan; each unit represents a right to receive one ordinary share and the RSUs are scheduled to vest in full on July 24, 2026 subject to service and plan conditions. The filing shows these units recorded at a $0.0 acquisition price for reporting purposes.
On 08/08/2025 the reporting person disposed of 1,805 ordinary shares at a price of $111.2502 per share to satisfy tax obligations arising from the vesting of previously granted RSUs. After the transactions the filing lists 10,837 shares beneficially owned by the reporting person.
Rick E Winningham, a director of Jazz Pharmaceuticals (JAZZ), reported a grant of 3,507 restricted stock units on 08/07/2025. Each restricted stock unit represents a contingent right to receive one ordinary share and, subject to continued service and conditions, the units are scheduled to vest in full on July 24, 2026. The grant is under the issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan and is reported with an acquisition price of $0.00.
The filing also discloses a sale on 08/08/2025 of 1,805 shares at $111.2524 described as shares sold to satisfy tax obligations arising from prior RSU vesting. Reported beneficial ownership moved from 16,198 shares after the grant to 14,393 shares after the sale.
Seamus Mulligan, a director of Jazz Pharmaceuticals (JAZZ), was granted 3,507 restricted stock units on 08/07/2025. Each unit represents a contingent right to one ordinary share and, subject to continuous service and plan conditions, the units will vest in full on July 24, 2026.
Following the reported transaction, the filing shows the reporting person beneficially owns 1,179,613 shares directly and 101,621 shares indirectly through Nerano Pharma Limited, an entity owned and controlled by the reporting person and his immediate family. The grant was made under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
Renee D. Gala, President & CEO of Jazz Pharmaceuticals (JAZZ), reported a grant of 18,808 restricted stock units (RSUs) under the Issuer's 2011 Equity Incentive Plan with a vesting schedule measured from a September 2025 commencement date. Each RSU represents a contingent right to one ordinary share and vests in equal annual installments over four years, with one-quarter vesting on the first anniversary. The filing also discloses acquisition of 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Following the reported transactions, Ms. Gala beneficially owns 107,869 ordinary shares.
Form 144 notice for Jazz Pharmaceuticals (JAZZ) reports a proposed sale of 3,731 common shares on NASDAQ with an aggregate market value of $417,872. The form lists total shares outstanding as 60,658,809 and an approximate sale date of 08/08/2025.
The shares were acquired on 08/07/2025 through restricted stock vesting from the issuer and the form records payment/compensation as of 08/07/2025. ETRADE FINANCIAL CORPORATION is named as the broker. The filer indicates no securities sold in the past three months and attests they are not aware of undisclosed material adverse information about the issuer.
The filing is a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The securities are listed as outstanding in the amount of 60,658,809 shares and the proposed sale is identified for 08/08/2025 on NASDAQ.
The shares were acquired on 08/07/2025 as restricted stock vesting from the issuer and the consideration is listed as compensation. The form notes "Nothing to Report" for securities sold during the past three months. Several filer contact fields (including CIK and submission contact details) appear blank in the provided content.
Jazz Pharmaceuticals (JAZZ) submitted a Form 144 reporting a proposed sale of 3,731 shares of common stock through ETRADE Financial Corporation on 08/08/2025 with an aggregate market value of $417,872. The filing shows the shares were acquired on 08/07/2025 through restricted stock vesting and were granted as compensation. The form states there were no securities sold in the past three months by the selling person and includes the seller's certification that they are not aware of undisclosed material adverse information about the issuer. The shares represent a very small fraction of the 60,658,809 shares outstanding.
Jazz Pharmaceuticals (JAZZ) filed a Rule 144 notice reporting a proposed sale of 3,731 common shares with an aggregate market value of $417,872. The sale is scheduled on NASDAQ for 08/08/2025 and lists E*TRADE Financial Corporation as broker.
The filing shows these shares were acquired on 08/07/2025 through restricted stock vesting from the issuer and were paid as compensation. The filing also reports 60,658,809 shares outstanding and notes "Nothing to Report" for securities sold in the past three months.
Form 144 notice reports a proposed sale of 3,731 shares of common stock of ETRADE FINANCIAL CORPORATION on NASDAQ with an aggregate market value of $417,872 and 60,658,809 shares outstanding. The securities were acquired on 08/07/2025 through restricted stock vesting from the issuer and the reported payment/nature is compensation. The proposed sale date is 08/08/2025. The filer reports no securities sold in the past three months and the filing is marked LIVE. The form includes the standard representation that the seller does not possess undisclosed material adverse information and references trading-plan/Rule 10b5-1 considerations.
Jazz Pharmaceuticals filed a Form 144 reporting a proposed sale of 3,731 shares of common stock with an aggregate market value of $417,872. The shares represent restricted stock that vested on 08/07/2025 and were acquired as compensation. The filer intends to sell the shares on or about 08/08/2025 on NASDAQ through ETRADE FINANCIAL CORPORATION. The company shows 60,658,809 shares outstanding and reports Nothing to Report for securities sold in the past three months. The notice includes the standard representation that the seller is unaware of any undisclosed material adverse information about the issuer.